Pharmacyclics, Inc. (PCYC) Tops Q4 EPS Views, Bolstered by Strong Collaboration Revenue
Tweet Send to a Friend
Pharmacyclics, Inc. (NASDAQ: PCYC) reported Q4 EPS of $0.95, $0.28 better than the analyst estimate of $0.67. Revenue for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
